LPIN1
LPIN1 (lipin 1, also known as KIAA0188) is a magnesium-dependent phosphatidate phosphatase that converts phosphatidic acid to diacylglycerol. It also acts as a nuclear transcriptional coactivator, linking triglyceride and phospholipid synthesis to the control of lipid metabolism gene expression. Browse Assay Genie's current range of LPIN1 research reagents below, or read on for the biology behind the target.
LPIN1 is a magnesium-dependent phosphatidic acid phosphohydrolase. It catalyses the dephosphorylation of phosphatidic acid to yield diacylglycerol, the penultimate step in triglyceride synthesis. The same reaction supplies diacylglycerol for phosphatidylcholine and phosphatidylethanolamine biosynthesis, so the enzyme controls fatty acid metabolism at several levels. LPIN1 is also recruited to the outer mitochondrial membrane, where its conversion of phosphatidic acid to diacylglycerol is involved in mitochondrial fission.
Beyond its enzymatic role, the LPIN1 protein acts in the nucleus as a transcriptional coactivator. It works with the PPARGC1A/PPARA regulatory pathway, and with some peroxisome proliferator-activated receptors, to modulate expression of genes involved in lipid metabolism. Expression of the LPIN1 gene is required for adipocyte differentiation. UniProt records the protein in the cytosol, the endoplasmic reticulum membrane and the nuclear membrane, and places it in the lipin family. HGNC groups the gene with the lipins and with microRNA protein coding host genes. The mouse ortholog is Lpin1.
Mutations in LPIN1 are associated with metabolic syndrome, type 2 diabetes, acute recurrent rhabdomyolysis and autosomal recessive acute recurrent myoglobinuria (ARARM). The gene is also a candidate for several human lipodystrophy syndromes. This combination of lipid-synthetic and gene-regulatory activity makes LPIN1 a useful target for studying how cells coordinate lipid storage, membrane phospholipid supply and metabolic transcription programmes.
LPIN1 converts phosphatidic acid to diacylglycerol, supporting triglyceride, phosphatidylcholine and phosphatidylethanolamine biosynthesis.
LPIN1 expression is required for adipocyte differentiation, making it relevant to studies of fat cell development and lipodystrophy.
In the nucleus LPIN1 coactivates the PPARGC1A/PPARA pathway to modulate expression of lipid metabolism genes.
LPIN1 mutations are linked to metabolic syndrome, type 2 diabetes, recurrent rhabdomyolysis and myoglobinuria.
LPIN1 is a magnesium-dependent phosphatidate phosphatase that converts phosphatidic acid to diacylglycerol during triglyceride, phosphatidylcholine and phosphatidylethanolamine synthesis. It also acts as a nuclear coactivator for the PPARGC1A/PPARA pathway and is involved in mitochondrial fission and adipocyte differentiation.
The HGNC name is lipin 1, and the UniProt protein name is phosphatidate phosphatase LPIN1. The gene was previously known by the alias KIAA0188. The enzyme is classified as EC 3.1.3.4 and belongs to the lipin family.
LPIN1 mutations are associated with metabolic syndrome, type 2 diabetes, acute recurrent rhabdomyolysis and ARARM, and the gene is a candidate for lipodystrophy syndromes. The mouse ortholog is Lpin1; check the datasheet of any product for its validated reactivity.
Other lipins, PPAR pathway partners and lipid metabolism targets with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q14693; product specifications from Assay Genie datasheets.